NYSE:CTST - CannTrust Stock Price, Forecast & News

CannTrust trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTST."

CannTrust is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for CannTrust.

8 brokerages have issued twelve-month price objectives for CannTrust's shares. Their forecasts range from C$2.00 to C$7.00. On average, they expect CannTrust's stock price to reach C$4.50 in the next year. This suggests a possible upside of 324.5% from the stock's current price. View Analyst Price Targets for CannTrust.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CannTrust in the last year. There are currently 1 sell rating, 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for CannTrust.

News stories about CTST stock have trended somewhat negative this week, InfoTrie reports. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. CannTrust earned a coverage optimism score of -1.9 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for CannTrust.

CannTrust saw a decline in short interest in December. As of December 13th, there was short interest totalling 12,050,000 shares, a decline of 8.2% from the November 28th total of 13,120,000 shares. Based on an average daily trading volume, of 1,970,000 shares, the days-to-cover ratio is currently 6.1 days. Currently, 10.1% of the shares of the company are sold short. View CannTrust's Current Options Chain.

Some companies that are related to CannTrust include AC Immune (ACIU), Morphic (MORF), Kadmon (KDMN), MacroGenics (MGNX), Kura Oncology (KURA), Neoleukin Therapeutics (NLTX), Crinetics Pharmaceuticals (CRNX), Magenta Therapeutics (MGTA), Milestone Pharmaceuticals (MIST), Prothena (PRTA), BioDelivery Sciences International (BDSI), Molecular Templates (MTEM), Axovant Sciences (AXON), Clovis Oncology (CLVS) and Viking Therapeutics (VKTX).

Based on aggregate information from My MarketBeat watchlists, some companies that other CannTrust investors own include Aurora Cannabis (ACB), Canopy Growth (CGC), Aphria (APHA), KushCo (KSHB), Cronos Group (CRON), Aurora Cannabis (ACB), OrganiGram (OGI), HEXO (HEXO), Nokia Oyj (NOK) and Aphria (APHA).

Shares of CTST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CTST stock can currently be purchased for approximately C$1.06.

CannTrust has a market capitalization of C$149.98 million and generates C$35.22 million in revenue each year. The company earns C$-10,460,000.00 in net income (profit) each year or C($0.11) on an earnings per share basis. CannTrust employs 576 workers across the globe.View Additional Information About CannTrust.

The official website for CannTrust is http://www.canntrust.ca/.

CannTrust's mailing address is 3280 LANGSTAFF ROAD UNIT 1, VAUGHAN A6, L4K 4Z8. The company can be reached via phone at 64-7872-2300 or via email at [email protected]